Market Cap : 59.32 M | Enterprise Value : 64.7 M | PE Ratio : At Loss | PB Ratio : 1.49 |
---|
NAS:ORGS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ORGS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Orgenesis's Total Inventories for the quarter that ended in Mar. 2022 was $0.12 Mil. Orgenesis's Revenue for the three months ended in Mar. 2022 was $7.21 Mil. Orgenesis's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.02.
Orgenesis's Inventory-to-Revenue for the quarter that ended in Mar. 2022 declined from Dec. 2021 (0.02) to Dec. 2021 (0.02)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueDays Inventory indicates the number of days of goods in sales that a company has in the inventory. Orgenesis's Days Inventory for the three months ended in Mar. 2022 was 14.76.
Total Inventories can be measured by Days Sales of Inventory (DSI). Orgenesis's days sales of inventory (DSI) for the three months ended in Mar. 2022 was 1.46.
Inventory Turnover measures how fast the company turns over its inventory within a year. Orgenesis's Inventory Turnover for the quarter that ended in Mar. 2022 was 6.18.
The historical data trend for Orgenesis's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Orgenesis's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Orgenesis's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Orgenesis's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orgenesis's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as
Inventory-to-Revenue (A: Dec. 2021 ) | |||||||
= | Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2020 ) | + | Total Inventories (A: Dec. 2021 )) | / | count ) | / | Revenue (A: Dec. 2021 ) |
= | ( (0.185 | + | 0.118) | / | 2 ) | / | 35.502 |
= | 0.1515 | / | 35.502 | ||||
= | 0.00 |
Orgenesis's Inventory-to-Revenue for the quarter that ended in Mar. 2022 is calculated as
Inventory-to-Revenue (Q: Mar. 2022 ) | |||||||
= | Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Dec. 2021 ) | + | Total Inventories (Q: Mar. 2022 )) | / | count ) | / | Revenue (Q: Mar. 2022 ) |
= | ( (0.118 | + | 0.113) | / | 2 ) | / | 7.212 |
= | 0.1155 | / | 7.212 | ||||
= | 0.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Orgenesis's Days Inventory for the three months ended in Mar. 2022 is calculated as:
Days Inventory | = | Total Inventories (Q: Mar. 2022 ) | / | Cost of Goods Sold (Q: Mar. 2022 ) | * | Days in Period |
= | 0.1155 | / | 0.714 | * | 365 / 4 | |
= | 14.76 |
2. Total Inventories can be measured by Days Sales of Inventory (DSI).
Orgenesis's Days Sales of Inventory for the three months ended in Mar. 2022 is
Days Sales of Inventory (DSI) | = | Total Inventories (Q: Mar. 2022 ) | / | Revenue (Q: Mar. 2022 ) | * | Days in Period |
= | 0.1155 | / | 7.212 | * | 365 / 4 | |
= | 1.46 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Orgenesis's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Mar. 2022 ) | / | Total Inventories (Q: Mar. 2022 ) |
= | 0.714 | / | 0.1155 | |
= | 6.18 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Orgenesis's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Sidransky David | director | JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205 |
Reithinger Neil | officer: CFO, Treasurer and Secretary | 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260 |
Philips Mario | director | C/O ATMI, INC DANBURY CT 06810 |
Ferber Sarah | officer: Chief Scientific Officer | 17B HAHASKALA STREET TEL AVIV L3 67890 |
Yachin Guy | director | 7 ORCHARD WAY N POTOMAC MD 20854 |
Nanda Ashish | director | 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452 |
Bedoret Denis | officer: See Remarks | 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041 |
Universite Libre De Bruxelles | other: less than 10% | AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050 |
Theodorus Ii Sa | other: less than 10% | ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
Theodorus Sca | other: less than 10% | ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
Belenger Olivier | other: less than 10% | DIEWEG, 69 BRUSSELS C9 1070 |
Shvartz Oded | 10 percent owner | 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000 |
Bultot Hugues | director | AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150 |
Buyse Chris Georges Frans | director | BAILLET LATOURLEI 119A BRUSSELS C9 2390 |
Tenne Joseph | officer: CFO Treasurer Secretary | 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511 |
From GuruFocus
Other Sources
By Seekingalpha 2021-11-06